Shandong Buchang Pharmaceuticals (603858.SH) has spent 528 million yuan to repurchase 3.03% of its shares.
BuXiang Pharmaceuticals (603858.SH) announced that as of September 18, 2024, the company has completed the central competitive bidding...
Shandong Buchang Pharmaceuticals (603858.SH) announced that as of September 18, 2024, the company has repurchased a total of 33.5555 million shares through centralized bidding trading. The repurchased shares account for 3.03% of the company's total share capital. The highest purchase price was 17.44 yuan per share and the lowest purchase price was 14.16 yuan per share. The total amount paid for the repurchases so far is 528 million yuan (excluding transaction fees).
 Related Articles 

WANG ON PPT (01243) purchased insurance for Executive Director and CEO Deng Haokang.

HANISON (00896) issues profit warning, expecting a net loss of approximately HK$270-280 million in the mid-term.

Pangang Group Vanadium & Titanium Resources (000629.SZ) has accumulated bought back 36.35 million shares, spending 101 million yuan.
WANG ON PPT (01243) purchased insurance for Executive Director and CEO Deng Haokang.

HANISON (00896) issues profit warning, expecting a net loss of approximately HK$270-280 million in the mid-term.

Pangang Group Vanadium & Titanium Resources (000629.SZ) has accumulated bought back 36.35 million shares, spending 101 million yuan.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


